Key Points
- CEO David James Lennon sold $93,465.84 of Whitehawk stock on April 2 (26,858 shares at $3.48), reducing his holding by 3.27% to 793,549 shares; he also sold 5,100 shares on March 2.
- WHWK shares trade around $3.50 with a 52‑week range of $1.39–$4.48 and a market cap of about $165.7M; analysts are mixed with a consensus "Hold" and an average target of $6.50, and the company recently reported quarterly EPS of ($0.34) that beat estimates of ($0.55).
Whitehawk Therapeutics, Inc. (NASDAQ:WHWK - Get Free Report) CEO David James Lennon sold 26,858 shares of the stock in a transaction that occurred on Thursday, April 2nd. The stock was sold at an average price of $3.48, for a total transaction of $93,465.84. Following the sale, the chief executive officer directly owned 793,549 shares of the company's stock, valued at approximately $2,761,550.52. This trade represents a 3.27% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.
David James Lennon also recently made the following trade(s):
- On Monday, March 2nd, David James Lennon sold 5,100 shares of Whitehawk Therapeutics stock. The shares were sold at an average price of $3.31, for a total transaction of $16,881.00.
Whitehawk Therapeutics Price Performance
Shares of WHWK stock opened at $3.51 on Friday. Whitehawk Therapeutics, Inc. has a fifty-two week low of $1.39 and a fifty-two week high of $4.48. The firm's 50 day moving average price is $3.28 and its two-hundred day moving average price is $2.66. The stock has a market cap of $165.66 million, a price-to-earnings ratio of 7.47 and a beta of 0.57.
Whitehawk Therapeutics (NASDAQ:WHWK - Get Free Report) last released its quarterly earnings data on Thursday, March 12th. The company reported ($0.34) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.55) by $0.21.
Analyst Ratings Changes
Several analysts recently issued reports on the company. Oppenheimer assumed coverage on Whitehawk Therapeutics in a report on Thursday, February 5th. They issued an "outperform" rating and a $6.00 price target for the company. JonesTrading initiated coverage on Whitehawk Therapeutics in a research report on Monday, December 22nd. They issued a "buy" rating and a $7.00 target price for the company. Weiss Ratings reiterated a "sell (d-)" rating on shares of Whitehawk Therapeutics in a research note on Friday, March 27th. Finally, Wall Street Zen upgraded Whitehawk Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday, March 21st. Two analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Hold" and an average target price of $6.50.
Read Our Latest Research Report on Whitehawk Therapeutics
Institutional Trading of Whitehawk Therapeutics
Several institutional investors and hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. bought a new position in Whitehawk Therapeutics during the 3rd quarter worth approximately $2,552,000. Peapod Lane Capital LLC acquired a new position in shares of Whitehawk Therapeutics in the 3rd quarter worth approximately $577,000. Dimensional Fund Advisors LP bought a new stake in shares of Whitehawk Therapeutics in the 3rd quarter valued at approximately $84,000. Avoro Capital Advisors LLC bought a new stake in shares of Whitehawk Therapeutics in the 3rd quarter valued at approximately $5,414,000. Finally, Suvretta Capital Management LLC acquired a new stake in shares of Whitehawk Therapeutics during the 3rd quarter valued at approximately $7,030,000. Institutional investors and hedge funds own 52.08% of the company's stock.
About Whitehawk Therapeutics
(
Get Free Report)
Aadi Bioscience, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
